

UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Minutes

Meeting Date: March 7, 2024
 Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
Meeting called to order		5:02PM EST		
A. Minutes from previous meetings		Review of Minutes from December 14, 2023	Minutes reviewed, approved	Yes
B. Formulary Review - New Drugs		Akeega		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Lodoco		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Ojjaara		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Bimzelx		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Fruzaqla		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Iyuzeh		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		OmvoH		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Velsipity		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Sohonos		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Jesduvroq		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Epogen		
		Recommendation: • Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Procrit		
		Recommendation: • Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Opfolda		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Pombiliti		
		Recommendation: • Medical Benefit with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Opvee		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Zurzuvae		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0

C. Formulary Review - PDL Modifications		Confirm Review of PDL Modifications Grid	Yes/No	Yes
		Recommendation: • Testosterone Gel Pump 1.62% : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Testosterone cypionate : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Testosterone enanthate : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Trientine 250mg : Move to preferred with Dx2Rx across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Amlodipine/ Benazepril : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Amlodipine/ Olmesartan : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Amlodipine/ Valsartan : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Irbesartan/ Hydrochlorothiazide : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Olmesartan/ Hydrochlorothiazide : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Valsartan/ Hydrochlorothiazide : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Mesalamine Capsule 0.375gm ER : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Mesalamine Tablet 1.2gm DR : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Mesalamine Capsule 400mg DR : Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Acyclovir Topical Ointment : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Uzedy : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Adalimumab- abdm : Move to preferred with prior authorization in the NY CHIP and NY EPP markets	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Amjevita- high concentration : Move to preferred with prior authorization in the NY CHIP and NY EPP markets	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Cyltezo : Move to non-preferred with prior authorization in the NY CHIP and NY EPP markets	Motion made, seconded, and carried to accept recommendation	9:0
		Recommendation: • Amjevita- low concentration : Move to non-preferred with prior authorization in the NY CHIP and NY EPP markets	Motion made, seconded, and carried to accept recommendation	9:0
D. Formulary Review - New Drugs- Medical		Confirm Review of New Drugs- Medical Grid	Yes/No	Yes
		Veopoz		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Izervay		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Daxxify		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0
		Aphexda		
		Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	9:0

E. Formulary Review - Drugs Evaluated Per Grid	██████████	Apply recommendations as outlined in grid	Motion made, seconded, and carried to accept recommendation	9:0
F. Clinical Guidelines	██████████	Clinical Guideline Review		
		Apply New Pharmacy Guidelines	Motion made, seconded, and carried to accept recommendation	9:0
		Continue to Apply Pharmacy Guidelines Requiring Modifications	Motion made, seconded, and carried to accept recommendation	9:0
		Remove Pharmacy Guidelines Requiring Archival	Motion made, seconded, and carried to accept recommendation	9:0
G. Quality Monitoring	██████████	Confirm Review of Quality Data	Yes/No	Yes
	██████████	DUR Review		
	██████████	Drug Recalls – 4th Quarter 2023		
	██████████	Top 25 Drugs by Spend and Volume – 4th Quarter 2023		
	██████████	Top 10 Drugs Requested - Approvals and Denials – 4th Quarter 2023		
	██████████	Grievances and Appeals Data – 4th Quarter 2023		
	██████████	Inter-Rater Reliability (IRR) – 4th Quarter 2023 • Pharmacists		
H. Additional Comments/Questions	██████████	██████████ asked about shortages of ADHD medications; ██████████ answered, we are handling these shortages on a market to market basis. ██████████ stated, there are help desk processes in place at OptumRx to provide override for payment for brand when a member can't get a generic medication during shortages; we also work with our health plan pharmacists to address shortages. Shortages appear to be regional and sporadic; there have also been PDL expansions to accommodate. We have put these processes in place for all drug shortages within the last year and a half, not strictly for ADHD medications.		
Adjournment	██████████		6:57PM EST	
Respectfully Submitted to the Committee, ██████████ ██████████ ██████████ UHC C&S				